CY1119448T1 - N-(5S,6S,9R)-5-AMlNO-6-(2,3-ΔΙΦΘOPOΦAINYΛ)-6,7,8,9-TETPAΫΔPO-5H-ΚΥΚΛΟΕΠΤΑ[Β]ΠΥΡΙΔΙΝ-9-ΥΛ-4-(2-ΟΞΟ-2, 3-ΔΙΫΔΡΟ-1Η-ΙΜΙΔΑΖΟ[4,5-Β] ΠΥΡΙΔΙΝ-1-ΥΛ)ΠΙΠΕΡΙΔΙΝΟ-1-ΚΑΡΒΟΞΥΛΙΚΟ, ΗΜΙ-ΘΕΙΙΚΟ ΑΛΑΣ - Google Patents

N-(5S,6S,9R)-5-AMlNO-6-(2,3-ΔΙΦΘOPOΦAINYΛ)-6,7,8,9-TETPAΫΔPO-5H-ΚΥΚΛΟΕΠΤΑ[Β]ΠΥΡΙΔΙΝ-9-ΥΛ-4-(2-ΟΞΟ-2, 3-ΔΙΫΔΡΟ-1Η-ΙΜΙΔΑΖΟ[4,5-Β] ΠΥΡΙΔΙΝ-1-ΥΛ)ΠΙΠΕΡΙΔΙΝΟ-1-ΚΑΡΒΟΞΥΛΙΚΟ, ΗΜΙ-ΘΕΙΙΚΟ ΑΛΑΣ

Info

Publication number
CY1119448T1
CY1119448T1 CY20171101052T CY171101052T CY1119448T1 CY 1119448 T1 CY1119448 T1 CY 1119448T1 CY 20171101052 T CY20171101052 T CY 20171101052T CY 171101052 T CY171101052 T CY 171101052T CY 1119448 T1 CY1119448 T1 CY 1119448T1
Authority
CY
Cyprus
Prior art keywords
pyridin
sulfate
semi
compound
inflammation
Prior art date
Application number
CY20171101052T
Other languages
English (en)
Inventor
Daniel Richard Roberts
Richard Raymond Schartman
Chenkou Wei
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119448(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1119448T1 publication Critical patent/CY1119448T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Αποκαλύπτεται ημιθειικό άλας της Ένωσης (I): και κρυσταλλικές μορφές του ημιθειικού άλατος. Επίσης αποκαλύπτονται μέθοδοι χρήσης του ημιθειικού άλατος της Ένωσης (I) ως ανταγωνιστή υποδοχέα CGRP και φαρμακευτικών συνθέσεων που περιλαμβάνουν το ημιθειικό άλας της Ένωσης (I). Το ημιθειικό άλας της Ένωσης (I) είναι χρήσιμο στην θεραπεία, αποτροπή ή ανακούφιση διαταραχών που συμπεριλαμβάνουν ημικρανία και άλλες κεφαλαλγίες, νευρογενή αγγειοδιαστολή, νευρογενή φλεγμονή, θερμική βλάβη, κυκλοφορικό σοκ, έξαψη που σχετίζεται με εμμηνόπαυση, φλεγμονώδεις ασθένειες της αναπνευστικής οδού, όπως άσθμα και χρόνια αποφρακτική πνευμονοπάθεια(COPD).
CY20171101052T 2012-02-27 2017-10-10 N-(5S,6S,9R)-5-AMlNO-6-(2,3-ΔΙΦΘOPOΦAINYΛ)-6,7,8,9-TETPAΫΔPO-5H-ΚΥΚΛΟΕΠΤΑ[Β]ΠΥΡΙΔΙΝ-9-ΥΛ-4-(2-ΟΞΟ-2, 3-ΔΙΫΔΡΟ-1Η-ΙΜΙΔΑΖΟ[4,5-Β] ΠΥΡΙΔΙΝ-1-ΥΛ)ΠΙΠΕΡΙΔΙΝΟ-1-ΚΑΡΒΟΞΥΛΙΚΟ, ΗΜΙ-ΘΕΙΙΚΟ ΑΛΑΣ CY1119448T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603598P 2012-02-27 2012-02-27
PCT/US2013/027648 WO2013130402A1 (en) 2012-02-27 2013-02-25 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt

Publications (1)

Publication Number Publication Date
CY1119448T1 true CY1119448T1 (el) 2018-03-07

Family

ID=47844498

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171101052T CY1119448T1 (el) 2012-02-27 2017-10-10 N-(5S,6S,9R)-5-AMlNO-6-(2,3-ΔΙΦΘOPOΦAINYΛ)-6,7,8,9-TETPAΫΔPO-5H-ΚΥΚΛΟΕΠΤΑ[Β]ΠΥΡΙΔΙΝ-9-ΥΛ-4-(2-ΟΞΟ-2, 3-ΔΙΫΔΡΟ-1Η-ΙΜΙΔΑΖΟ[4,5-Β] ΠΥΡΙΔΙΝ-1-ΥΛ)ΠΙΠΕΡΙΔΙΝΟ-1-ΚΑΡΒΟΞΥΛΙΚΟ, ΗΜΙ-ΘΕΙΙΚΟ ΑΛΑΣ
CY20191100951T CY1122121T1 (el) 2012-02-27 2019-09-11 N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191100951T CY1122121T1 (el) 2012-02-27 2019-09-11 N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας

Country Status (25)

Country Link
US (1) US8759372B2 (el)
EP (2) EP3254681B1 (el)
JP (2) JP6208154B2 (el)
KR (2) KR102220969B1 (el)
CN (1) CN104136437B (el)
AU (1) AU2013226361B2 (el)
BR (1) BR112014021032B1 (el)
CA (1) CA2865585C (el)
CY (2) CY1119448T1 (el)
DK (2) DK2820016T3 (el)
EA (1) EA025358B1 (el)
ES (2) ES2642737T3 (el)
HK (1) HK1248111B (el)
HR (2) HRP20171620T1 (el)
HU (2) HUE047050T2 (el)
IL (1) IL234272B (el)
LT (2) LT3254681T (el)
MX (1) MX352171B (el)
NO (1) NO2935439T3 (el)
PL (2) PL2820016T3 (el)
PT (2) PT3254681T (el)
RS (2) RS56556B1 (el)
SG (1) SG11201404834XA (el)
SI (2) SI3254681T1 (el)
WO (1) WO2013130402A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347229B (es) 2012-01-26 2017-04-19 Christopher J Soares Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.
BR112014021032B1 (pt) * 2012-02-27 2022-09-27 Bristol-Myers Squibb Company Sal hemissulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluoro-fenil)-6,7,8,9-tetra-hidro-5h- iclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il}-piperidina-1-carboxilato, seu uso e composição farmacêutica que o compreende
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
KR20220025914A (ko) 2015-03-06 2022-03-03 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
IL265099B1 (en) * 2016-09-02 2024-05-01 Christopher J Soares Medicinal compositions containing an effective amount of a calcitonin gene-related peptide (CGRP) receptor antagonist, or a pharmaceutically acceptable salt thereof, for the treatment of glaucoma
KR20190043602A (ko) 2016-09-07 2019-04-26 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
MY201105A (en) 2017-02-01 2024-02-06 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
KR20200135465A (ko) * 2018-03-25 2020-12-02 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. Cgrp 관련 장애를 위한 리메게판트
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US20210338654A1 (en) * 2019-01-20 2021-11-04 Biohaven Pharmaceutical Holding Company Ltd. Cgrp antagonists for treating migraine breakthrough
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR20230157986A (ko) 2021-03-02 2023-11-17 체게에르페 다이어그노스틱스 게엠베하 편투통 발생의 치료 및/또는 저감
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
AR126954A1 (es) * 2021-09-02 2023-12-06 Biohaven Pharm Holding Co Ltd Métodos para tratar la psoriasis con uno o más antagonistas de receptores de cgrp
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164A (zh) * 2022-01-27 2023-08-08 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24500A1 (fr) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2005085228A1 (ja) 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. シクロアルカノピリジン誘導体
CA2583536A1 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
EP1804919B1 (en) 2004-10-22 2011-03-30 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CA2649158A1 (en) 2006-04-10 2007-10-25 Merck & Co., Inc. Process for the preparation of pyridine heterocycle cgrp antagonist intermediate
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
BR112014021032B1 (pt) * 2012-02-27 2022-09-27 Bristol-Myers Squibb Company Sal hemissulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluoro-fenil)-6,7,8,9-tetra-hidro-5h- iclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il}-piperidina-1-carboxilato, seu uso e composição farmacêutica que o compreende

Also Published As

Publication number Publication date
KR20200016993A (ko) 2020-02-17
NO2935439T3 (el) 2018-03-31
HUE034936T2 (hu) 2018-03-28
DK3254681T3 (da) 2019-09-30
CA2865585A1 (en) 2013-09-06
CN104136437A (zh) 2014-11-05
ES2642737T3 (es) 2017-11-17
LT2820016T (lt) 2017-10-25
BR112014021032A2 (el) 2017-06-20
SI3254681T1 (sl) 2019-10-30
KR20140130140A (ko) 2014-11-07
PT2820016T (pt) 2017-10-18
PL3254681T3 (pl) 2019-12-31
CY1122121T1 (el) 2020-11-25
KR102076118B1 (ko) 2020-02-11
HRP20171620T1 (hr) 2017-12-01
DK2820016T3 (da) 2017-11-13
HRP20191655T1 (hr) 2019-12-13
EA201491585A1 (ru) 2015-01-30
CN104136437B (zh) 2016-05-11
WO2013130402A1 (en) 2013-09-06
EA025358B1 (ru) 2016-12-30
AU2013226361B2 (en) 2017-09-21
KR102220969B1 (ko) 2021-02-25
MX352171B (es) 2017-11-13
HUE047050T2 (hu) 2020-04-28
ES2746031T3 (es) 2020-03-04
JP2017226693A (ja) 2017-12-28
BR112014021032B1 (pt) 2022-09-27
JP6476253B2 (ja) 2019-02-27
CA2865585C (en) 2019-12-10
PT3254681T (pt) 2019-10-01
EP3254681B1 (en) 2019-06-19
SI2820016T1 (sl) 2017-11-30
US8759372B2 (en) 2014-06-24
RS59295B1 (sr) 2019-10-31
JP2015511581A (ja) 2015-04-20
EP2820016A1 (en) 2015-01-07
MX2014009544A (es) 2014-11-10
PL2820016T3 (pl) 2018-01-31
EP3254681A1 (en) 2017-12-13
IL234272B (en) 2018-10-31
US20130225636A1 (en) 2013-08-29
AU2013226361A1 (en) 2014-10-16
RS56556B1 (sr) 2018-02-28
LT3254681T (lt) 2019-09-25
SG11201404834XA (en) 2014-09-26
JP6208154B2 (ja) 2017-10-04
HK1248111B (zh) 2020-04-17
EP2820016B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
CY1119448T1 (el) N-(5S,6S,9R)-5-AMlNO-6-(2,3-ΔΙΦΘOPOΦAINYΛ)-6,7,8,9-TETPAΫΔPO-5H-ΚΥΚΛΟΕΠΤΑ[Β]ΠΥΡΙΔΙΝ-9-ΥΛ-4-(2-ΟΞΟ-2, 3-ΔΙΫΔΡΟ-1Η-ΙΜΙΔΑΖΟ[4,5-Β] ΠΥΡΙΔΙΝ-1-ΥΛ)ΠΙΠΕΡΙΔΙΝΟ-1-ΚΑΡΒΟΞΥΛΙΚΟ, ΗΜΙ-ΘΕΙΙΚΟ ΑΛΑΣ
PH12017500146A1 (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
TN2012000139A1 (en) Cgrp receptor antagonists
CO2018002829A2 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
TN2015000005A1 (en) Azaindole derivatives which act as pi3k inhibitors
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
EA201391239A1 (ru) Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
MX2014014710A (es) Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar).
CL2016000187A1 (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad antagonista de receptores muscarínicos así como actividad agonista del receptor b2 adrenérgico.
BR112015014701B8 (pt) Derivados de benzimidazol e seus usos
PH12015501339A1 (en) Indole carboxamide derivatives as p2x7 receptor antagonists
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
UA109867C2 (ru) Замещенные соединения пиразола как антагонисты рецепторов лизофосфатидной кислоты (lpar)
MX2016009581A (es) Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso.
MX2017004852A (es) Inhibidores de aldosterona sintasa.
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
UA109942C2 (ru) Производные 2-амино-3-(имидазол-2-ил)-пиридин-4-она и их применение как ингибиторов киназы рецептора vegf
CL2017002605A1 (es) Derivados de indol
WO2014147636A8 (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao